SynthesisAnnals of African medicine2026
Diagnostic Accuracy of the Serum-free Androgen Index in Diagnosing Polycystic Ovary Syndrome: An Updated Systematic Review and Meta-analysis.
Synthesis in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative analysis of hormonal and metabolic indices in phenotypic subgroups of polycystic ovary syndrome.Journal of the Turkish German Gynecological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the diagnostic accuracy of the free androgen index (FAI) in diagnosing polycystic ovary syndrome (PCOS).
methodsWe systematically searched PubMed, Cochrane Library, and Google Scholar databases for relevant studies published up to June 2024. The inclusion criteria were studies that reported the sensitivity and specificity of FAI for PCOS diagnosis. We used a random-effects model to find the pooled sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operating characteristic area under the curve (SROC AUC). We determined positive and negative likelihood ratios (NLRs) using the Fagan nomogram and assessed heterogeneity using I2 statistics. We performed meta-regression and subgroup analysis to explore sources of heterogeneity and used Deeks' funnel plot to assess publication bias. This study is registered with PROSPERO (ID: CRD42024546829).
resultsWe included 14 studies with 2870 PCOS patients and 3985 non-PCOS controls. Pooled sensitivity and specificity were 0.81 (95% confidence interval [CI]; 0.73-0.86) and 0.82 (95% CI; 0.72-0.90), respectively. The positive and NLRs were 4.6 (95% CI; 2.8-7.6) and 0.23 (95% CI; 0.17-0.33), respectively. The DOR was 20 (95% CI: 10-39), and the SROC AUC was 0.88 (95% CI: 0.85-0.90). Variability in FAI cutoff values contributed significantly to heterogeneity across studies.
conclusionSerum FAI is a reliable biomarker for diagnosing PCOS, demonstrating sensitivity and specificity exceeding 80%. It is particularly valuable in primary care settings where ultrasound facility is unavailable. FAI assists in diagnosing biochemical hyperandrogenism, especially in cases where clinical criteria are inconclusive.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.